KRAS変異CRCの潜在的な戦略としてのPRMT5阻害:PRMT5-KRASクロストックの下流媒介
Mark Spivak1, Moshe Pahmer2, Dorna Delrahimnia3
1College of Medicine, SUNY Downstate Health Sciences University, Brooklyn, NY 11203, USA.
Current issues in molecular biology
|August 27, 2025
まとめ
研究者らは,MYC,E2F1,EIF4Eを,タンパク質アルギニンメチルトランスファーゼ5 (PRMT5) と結腸直腸がん (CRC) のクロストークを媒介する重要なタンパク質として特定した. この発見は,KRAS変異性CRC,挑戦的ながんサブタイプに対する新たな治療標的を提示しています.
科学分野:
- 腫瘍学
- 分子生物学
- エピジェネティクス
背景:
- 結腸直腸がん (CRC) は,世界中で癌による死亡の主な原因です.
- KRAS変異は,約45%のCRC症例で発生し,予後が悪くなり,治療の選択肢が限られている.
- プロテインアルギニンメチルトランスフェラーゼ5 (PRMT5) は表遺伝子調節剤であり,前回の研究でKRAS変異CRC細胞においてより高い有効性を示した.
研究 の 目的:
- 大腸がんにおけるPRMT5とKRASの相互作用 (クロスストーク) を媒介する下流タンパク質を特定する.
- PRMT5阻害剤で治療されたKRAS変異体と野生型CRCとの間の観察された治療上の違いの潜在的分子メカニズムを調査する.
主な方法:
- 候補タンパク質を特定するための文献レビュー.
- STRINGデータベースを用いたタンパク質対タンパク質相互作用分析
- 患者データに関するGEPIAデータベースを用いた遺伝子発現分析と相関研究.
主要な成果:
- MYC,E2F1,およびEIF4Eは,PRMT5- KRASのクロストラックに関与する重要な候補タンパク質として特定されました.
- これらの候補タンパク質はPRMT5とKRASの両方と相互作用する.
- MYC,E2F1,EIF4EはCRC腫瘍で過剰発現しており,患者データではPRMT5およびKRAS遺伝子発現と正の相関関係にある.
結論:
- この研究は,大腸がんにおけるPRMT5- KRASのクロストークに関する新しい洞察を提供します.
- MYC,E2F1,EIF4Eは,この相互作用の主要な媒介物として提案されています.
- これらの発見は,KRAS変異性CRCに対する潜在的な新しい治療目標と組み合わせ戦略を示唆し,さらなる実験的検証を正当化しています.
さらに関連する動画
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.1K
08:11Quantitative Methods to Study Protein Arginine Methyltransferase 1-9 Activity in Cells
Published on: August 7, 2021
4.3K
関連する概念動画
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K
The Ras Gene
6.4K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.4K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
